TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04234971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention group (DBM/BMP)
Description: All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
Study: NCT06239246

Intervention type: OTHER
Intervention: Behavioral
Description: Psychotherapy: Cognitive-behavioral therapy (CBT), Internet-based cognitive-behavioral therapy (I-CBT), cognitive-behavioral therapy for insomnia (CBT-I), self-management education for heart failure, blended intervention; Drug treatment (cardiovascular drugs: aspirin, clopidogrel, ticagrelor, statins; psychiatric drugs: SSRIs, SNRIs, etc.);
Study: NCT05290987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal spray
Description: 2 sprays in each nostril, 6 times a day

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: nasal spray
Description: 2 sprays in each nostril, 6 times a day
Study: NCT04234971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group(autologous ICBG)
Description: The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
Study: NCT05683574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo
Description: Participants randomized to this group will receive one (01) capsule of the investigational drug and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib 90 mg (Arcoxia®) +FDC placebo
Description: Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia®) and one (01) FDC placebo capsule, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclobenzaprine hydrochloride + etoricoxib placebo
Description: Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul®) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
Study: NCT04857437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07202954 Repeat Dose
Description: 10, 30, 100, 300, 600, 1200 milligrams (mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07202954 Single Dose
Description: 10, 30, 100, 300, 600, 900, 1200 milligrams (mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07202954 Single Dose
Description: 10, 30, 100, 300, 600, 900, 1200 milligrams (mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study: NCT06542120

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Auscultation and Echocardiography
Description: Heart auscultation will be done by pediatrician and echocardiography by echocardiologist
Study: NCT01027338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi exercise
Study: NCT06542120

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest Auscultation and Chest imaging examinations
Description: Chest auscultation will be done by pediatrician and chest imaging examinations by radiologist

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal Auscultation and Abdominal imaging examinations
Description: Abdominal auscultation will be done by pediatrician and chest imaging examinations by radiologist
Study: NCT06336460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular Nerve Group (PENG) Block
Description: Under sterile technique, physician will identify relevant landmarks including the femoral artery, femoral vein, femoral nerve, ileopubic eminence (IPE), anterior inferior iliac spine (AIIS), psoas tendon (PT). Target area is bony space between AIIS and IPE adjacent to PT.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting fascial plane below the psoas tendon, above ilium bone. Landmark lies between the AIIS and IPE, just lateral to psoas tendon.~As needle tip reaches target, small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, lifting the psoas tendon from ilium, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush line of remaining anesthetic. Needle will then be withdrawn.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment (FIC) Block for Patients with Isolated Hip Fractures
Description: Under sterile technique, physician will identify relevant landmarks, including femoral artery, femoral vein, femoral nerve, iliacus muscle with overlying fascia iliaca.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting the fascial plane above iliacus muscle.~As needle tip reaches the target, a small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush the line of remaining anesthetic. The needle will then be withdrawn.
Study: NCT05130619

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Crossover meal study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Crossover meal study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Crossover meal study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Crossover meal study
Study: NCT05786378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Sample of patient's blood drawn at time of Treatment; the blood drawing occurs with addition of anticoagulant such as citrate dextrose A to prevent platelet activation prior to its use.~Obtain whole blood by venipuncture in acid citrate dextrose (ACD) tubes. Centrifuge the blood using a 'soft' spin. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~PRP activation prior to injection. PRP can be activated exogenously by calcium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anesthesia in external auditory canal
Description: local anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes
Study: NCT05464160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Muscular Vibration using the EVM EVO medical device (Endomedica, Italy)
Description: FMV will be applied 7 times per week for 3 weeks (21 total applications), using the EVM EVO medical device (Endomedica, Italy), applying an intensity of 100 Hz for a total of 23 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc...)
Study: NCT06456151

Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive candidiasis test
Description: The combination of acute phase marker monitoring and the T2Candida assay will be assessed.

Intervention type: OTHER
Intervention: Urine sample collection for future research
Description: Patients will be asked to provide a urine sample for future research (urine biobank).
Study: NCT05467761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Psilocybin
Description: 25mg orally
Study: NCT05786378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intratympanic Injection
Description: 0.5-1 ml of PRP will be injected in middle ear cavity in round window niche Using microscope or endoscope.
Study: NCT04764591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lateral sagittal approach
Description: Lateral sagittal approach for ultrasound guided infraclavicular brachial plexus block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Costoclavicular approach
Description: Costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
Study: NCT05467761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Psilocybin
Description: 5mg intravenously
Study: NCT05181774

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics
Description: Metabolomic data were obtained by UPLC-QTOF/MS platform.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics
Description: Metabolomic data were obtained by UPLC-QTOF/MS platform.
Study: NCT05912374

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)
Description: CHRP-BB is an evidence-informed behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. CHRP-BB consists of 4 weekly 50- minute sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)
Description: The enhanced version of CHRP-BB is an adapted behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. This intervention consists of 4 weekly 50- minute sessions that include cognitive dysfunction accommodation strategies.
Study: NCT05856682

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic-assisted TAP block(LATAP) and Rectus Sheath block
Description: Laparoscopic -assisted TAP and rectus sheath block will be performed after insertion of optical port By Surgeon /surgery trainee. • Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be anterior to the midaxillary line between the costal margin and iliac crest bilaterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic-assisted TAP block(LATAP) and Rectus Sheath block
Description: Laparoscopic -assisted TAP and rectus sheath block will be performed after insertion of optical port By Surgeon /surgery trainee. • Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be anterior to the midaxillary line between the costal margin and iliac crest bilaterally.
Study: NCT06543797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable rTMS
Description: Application of inhibitory low-frequency rTMS on unaffected primary motor cortex by wearable rTMS
Study: NCT04666831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT)
Description: The intervention combines AMI techniques as described by Miller and Rollnick (2013) in the third edition of their Motivational Interviewing book, as well as CBT techniques from the Tele-CBT protocol for bariatric surgery patients by Cassin et al. (2013).
Study: NCT06151951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Stabilization
Description: Isometric stretching and strengthening exercises of Neck flexor muscle including suboccipitalis, levator scapulae,scalnae anterior and upper trapezius. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Stabilization
Description: Isometric stretching and strengthening exercises of Neck flexor muscle including suboccipitalis, levator scapulae,scalnae anterior and upper trapezius. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Biofeedback
Description: In this method patients in supine position. Sphygmomanometer is used and 100 mmHg pressure will be maintained before the treatment start then cuff will be placed under the occiopit of spine and patient will be asked to press the cuff against the occiopit until gauze show target pressure then hold this position for 6 second and release. Repeated this pressure to 10 times, 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Biofeedback
Description: In this method Led Head Band light will be used as a visual feedback. Patients in sitting or standing position with neck straight with the alignment of front wall marking followed by control movement training. Patient will be asked to follow the marking through head band light while performing motion control training. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training.
Study: NCT05945134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual and auditory feedback STS training
Description: 30 minutes per session, 3 sessions per week, for a total of 3 weeks. The visual and auditory feedback signals will be given throughout the sit-to-stand movement. As the size of circle representing the weight bearing gets more even, and the mobile dot indicating the overall center of pressure moves forward and approaches the midline, the auditory cues will get louder to indicate proximity to the target. It allows the participants to adjust and relearn the correct weight shifting and symmetry.~The intensity will be adjusted based on different chair heights (e.g. 115%, 100%, 80% of lower leg length), various seat materials, and supported level of thigh (progressing from one-third of the length between the greater trochanter of the femur and the knee joint line to full support). The training program will be progressed according to the abilities of the participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional STS training
Description: 30 minutes per session, 3 sessions per week, for a total of 3 weeks. All settings will be the same as the experimental group, except for the feedback. In the control group, the verbal cues will be given by the physical therapist and a mirror will be placed in front of the participant for visual feedback. During the sit-to-stand movement, participants will be asked to try to maintain the alignment in the midline.
Study: NCT06350487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Enavogliflozin (0.3mg oral tablet once daily) will be administrated.
Study: NCT05732584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: structured family voice stimulation
Description: The structured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death. The content of the recording is developed according to the structured script.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unstructured family voice stimulation
Description: The unstructured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death.
Study: NCT04867681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education programme
Description: 4 individual sessions (S1, S2, S3, S4) of one hour each spread over 2 weeks, i.e. 2 sessions per week. S1 explains the different clinical signs and discusses the prognosis of the disease, S2 deals with the question of drug treatments, their different forms and their mechanisms of action. S3 discusses the evolution of the disease and the organisation of the care pathway. Finally, S4 looks at the aspects of quality of life, lifestyle and the fight against addictive co-morbidities, and concludes with a review of the patient's motivation and involvement in the subjects covered.
Study: NCT05945693

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The participants will perform aerobic-type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: The participants will perform aerobic-type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day for 16 weeks.
Study: NCT06494943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 inhibitor
Study: NCT06399068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: 1 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: 1 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: 1 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: 1 Tablet
Study: NCT06494943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110
Description: LAG-3 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110
Description: LAG-3 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum
Description: Chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Definitive surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Definitive surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation
Description: Adjuvant radiotherapy or chemoradiotherapy based on post-operative pathologic findings.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation
Description: Adjuvant radiotherapy or chemoradiotherapy based on post-operative pathologic findings.
Study: NCT06167434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Future Cardia™ Insertable Cardiac Monitoring (ICM) System
Description: The Future Cardia™ ICM procedure will be performed as a stand-alone procedure for subcutaneous insertion.
Study: NCT06296407

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard metabolic integrated rehabilitation protocol - duration 3 weeks
Description: Standard metabolic integrated rehabilitation protocol
Study: NCT06096974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-17231
Description: YL-17231 will be administered orally once daily in a continuous regimen